SOLICITATION NOTICE
B -- ERSPC Control Database
- Notice Date
- 8/26/2010
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100211-KM
- Archive Date
- 9/25/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Room 6070, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Control and Population Services (DCCPS), Surveillance Research Program (SRP), plans to procure on a sole source basis to obtain ERSPC Control Database for the Reconciliation of the PLCO and ERSPC Trial Results Using CISNET Models from the Institute of Cancer Research, SRD Building, Cotswold Road, Sutton Surrey, SM2 5NG United Kingdom. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award with one twelve (12) month option period. NCI’s Surveillance Research Program (SRP) has played a vital role in defining and establishing the national cancer surveillance systems, not only as a catalytic force but also as the source for substantive technical expertise that constitutes the system’s foundation. The New England Journal of Medicine published early results of the two largest randomized trials for PSA screening, the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial in the United States. While the ERSPC trial showed a 20% reduction in the rate of prostate cancer death due to PSA screening, the United States’ trial showed no benefit. Although these results may seem to be in conflict, it should be noted that there were many differences in the design and implementation of the two trials, such as differences in the PSA threshold used for biopsy, in contamination (i.e., PSA screening among men in the non-screening arm) and in baseline diagnosis and treatment practices. Because of these differences, the results are not immediately comparable. Modeling data from the trial represents a unique opportunity to reconcile results on the efficacy of PSA screening from the two trials. The purpose of this contract is to obtain data of cancer detection by age, stage and grade and contamination data from the control arm of the ERSPC trial as well as individual mortality data from the intervention and control arms of ERSPC for estimation of screening efficacy. The Cancer Screening Evaluation Unit (CSEU) at the Institute of Cancer Research (ICR) is uniquely qualified to perform the work outlined in this contract. The Institute of Cancer Research in the UK is one of the world's leading cancer research organizations and is internationally renowned for the quality of its science. The Cancer Screening Evaluation Unit (CSEU) is internationally recognized for its screening evaluation research. The CSEU conducts studies on the efficacy of screening for cancer, especially of the breast, cervix, colorectal and prostate; this includes large-scale, long-term trials of screening for cancer in sites where it is not yet of proven benefit, evaluation of existing screening programmes, and development of evaluation methods. They are known for conducting high quality research on screening evaluation for prostate cancer. Their work on prostate cancer includes the management and analysis of the central database for the European Randomised Trial of Screening for Prostate Cancer (ERSPC), crucial for the successful completion of this contract Most importantly, they are the sole access point to the central ERSPC database. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on September 10, 2010. For further information, please contact Karri Mares, Contract Specialist via electronic mail at maresk@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100211- KM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100211-KM/listing.html)
- Record
- SN02256897-W 20100828/100827000610-8d4f9b4e23ff14c0f8689c3da557a9b2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |